Announcements Trials
Browse Landscape

Phase

Phase NA 27Phase 2 6Phase 3 2Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 374Neoplasms 325Neoplasm Metastasis 289Leukemia, Myeloid, Acute 282Breast Neoplasms 276Colorectal Neoplasms 238Melanoma 196Ovarian Neoplasms 192Recurrence 185Multiple Myeloma 180Prostatic Neoplasms 157Pancreatic Neoplasms 156Lung Neoplasms 156Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 145Glioblastoma 145Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 117Carcinoma, Renal Cell 111Stomach Neoplasms 110Advanced Solid Tumors 108Glioma 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Brain Neoplasms 104Lymphoma 103Lymphoma, Large B-Cell, Diffuse 102Lymphoma, B-Cell 98Carcinoma, Hepatocellular 95Endometrial Neoplasms 92Lymphoma, Follicular 90

Interventions

ruxolitinib 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematopoietic and Lymphatic System Neoplasm × 1 year × Clear all
NCT07025538 2026-04-20

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

City of Hope Medical Center

Phase 1 Recruiting
42 enrolled

Hematopoietic and Lymphatic System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡